PTPA and cancer: We suggest that potentiating the anti-cancer activity of TMZ by inhibition of PP2A is caused by abrogation of the mitotic checkpoint by enhanced phosphorylation of Plk-1 and the simultaneous inhibition of cell cycle arrest in G1/S that results from the marked reduction in p53 driven by increased pMDM2.